A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information
NCT ID: NCT05718570
Last Updated: 2025-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
400 participants
OBSERVATIONAL
2023-02-03
2032-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with Adult Growth Hormone Deficiency (AGHD)
Participants will be treated with commercially available Sogroya according to routine clinical practice at the discretion of the treating physician. The decision to treat a participant with Sogroya has been made prior to and independently from the decision to include the participant in this study.
Somapacitan
Sogroya therapy in participants with AGHD.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Somapacitan
Sogroya therapy in participants with AGHD.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The decision to initiate treatment with commercially available Sogroya (somapacitan) has been made by the participant and the treating physician before and independently from the decision to include the participant in this study.
3. Male or female, age above or equal to 18 years assigned to Sogroya (somapacitan) treatment at the time of signing informed consent.
4. Diagnosis of adult growth hormone deficiency (AGHD) as per local practice.
Exclusion Criteria
2. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
3. Participant with hypersensitivity to the active substance or to any of the excipients.
4. Participant with active malignancy or in treatment for active pre-existing malignancy.
5. Participant with acute critical illness, suffering from complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure or similar conditions per investigator judgement.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Transparency (dept. 2834)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Barrow Neurological Institute
Phoenix, Arizona, United States
Keck Medical Center of USC - Outpatient Clinic
Los Angeles, California, United States
UCLA Health
Los Angeles, California, United States
Stanford Univ School of Med
Palo Alto, California, United States
Advanced Rx Clinical Research
Westminster, California, United States
Anschutz Outpatient Pavilion
Aurora, Colorado, United States
Metabolic Research Institute Inc
West Palm Beach, Florida, United States
Atlanta Diabetes Associates
Atlanta, Georgia, United States
Northwestern Medical Group
Chicago, Illinois, United States
Johns Hopkins University
Baltimore, Maryland, United States
Tufts Medical Center
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Brigham & Women's Hospital
Boston, Massachusetts, United States
Washington University
St Louis, Missouri, United States
UNMC
Omaha, Nebraska, United States
Palm Research Center Inc-Vegas
Las Vegas, Nevada, United States
Northern Nevada Endocrinology
Reno, Nevada, United States
NYU Langone Health
New York, New York, United States
Cornell University
New York, New York, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Physicians East Endocrinology
Greenville, North Carolina, United States
Oregon Health & Science University
Portland, Oregon, United States
St Lukes Physician Group
Center Valley, Pennsylvania, United States
Revival Research Institute, LLC
Dallas, Texas, United States
UT Southwestern Medical Center-CRU
Dallas, Texas, United States
EP Premier Medical Group PA
El Paso, Texas, United States
Consano Clinical Research, LLC
Shavano Park, Texas, United States
Puget Sound VA, University of Washington
Seattle, Washington, United States
University Of Washington_Seattle
Seattle, Washington, United States
HCL - HOPITAL LOUIS PRADEL - Service d'endocrinologie
Bron, , France
CHU LILLE - HOPITAL CLAUDE HURIEZ - Service d'endocrinologie et diabétologie
Lille, , France
APHM - HOPITAL DE LA CONCEPTION - Service d'endocrinologie
Marseille, , France
APHP - LA PITIE SALPETRIERE - Service endrocrinologie et medecine de la reproduction
Paris, , France
CHU REIMS - HOPITAL ROBERT DEBRE - Service Endocrinologie-Diabète-Nutrition
Reims, , France
Uniklinik Aachen - Endokrinologie und Diabetologie
Aachen, , Germany
Endokrinologikum Frankfurt
Frankfurt am Main, , Germany
Universitätsklinikum Halle - Innere Medizin III
Halle, , Germany
Universitätsmedizin der JGU Mainz - Endokrinologie und Stoffwechselerkrankungen
Mainz, , Germany
LMU Klinikum Großhadern München - Med. Klinik
München, , Germany
Medicover Neuroendokrinologie MVZ München
München, , Germany
Medicover Neuroendokrinologie MVZ
München, , Germany
Medicover MVZ Oldenburg
Oldenburg, , Germany
Medicover Oldenburg MVZ
Oldenburg, , Germany
Universitätsklinikum Würzburg - Zentrum für Innere Medizin (ZIM)
Würzburg, , Germany
Fukuoka University Chikushi Hospital_Endocrinology and Diabetes Mellitus
Chikushino-shi, Fukuoka, , Japan
Kagoshima University Hospital_Neurosurgery
Kagoshima-shi, Kagoshima, , Japan
Nippon Medical School Musashikosugi Hospital_Neurological Surgery
Kawasaki-shi, Kanagawa, , Japan
Kobe University Hospital_Diabetes and Endocrinology
Kobe-shi, Hyogo, , Japan
Okayama University Hospital_General Medicine
Okayama-shi, Okayama, , Japan
Osaka City General Hospital_Endocrinology and Diabetes Mellitus
Osaka-shi, Osaka, , Japan
Dr Soliman Fakeeh Hospital
Jeddah, , Saudi Arabia
My clinic
Jeddah, , Saudi Arabia
Dr. Sulaiman Al Habib Medical Group- Olaya
Riyadh, , Saudi Arabia
King Fahad Medical City
Riyadh, , Saudi Arabia
UKC Ljubljana, Endocrinology and Diabetes
Ljubljana, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NN8640-4515
Identifier Type: -
Identifier Source: org_study_id
U1111-1264-8642
Identifier Type: OTHER
Identifier Source: secondary_id